Clinic
Baptist Health
Baptist Health was paid $2.68M by Medicaid between Jan 2018 and Dec 2024, across 123 billing codes. Its largest line is 0241U, Neonatal screening for hereditary disorders, genomic sequence analysis panel — 13% of everything it billed.
33Billing provider infoBAPTIST HEALTH
MALVERN, AR 72104
MALVERN, AR 72104
33aNPI1902868391assigned 04/03/2006
33bProvider typeRehabilitation Clinic/Center
28Total paid$2.68M
24GClaims143,082
24DCodes billed123
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Arkansas
Rank by total paid#17 of 27
Median peer was paid$3.03M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WELLS, TROY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,164 | $276K | |
| 2019 | 25,480 | $358K | |
| 2020 | 17,629 | $347K | |
| 2021 | 20,927 | $404K | |
| 2022 | 24,459 | $572K | |
| 2023 | 20,767 | $471K | |
| 2024incomplete | 11,656 | $253K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 13% | 2,896 | 2,660 | $342K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10% | 1,665 | 1,521 | $269K |
| 70450 | Computed tomography, head or brain; without contrast material | 9.7% | 2,648 | 2,352 | $260K |
| 80053 | Comprehensive metabolic panel | 9.0% | 10,653 | 8,954 | $240K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.9% | 5,546 | 1,387 | $240K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.1% | 1,691 | 1,496 | $164K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 10,904 | 9,009 | $80K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 1,516 | 1,275 | $62K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 732 | 668 | $54K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 4,606 | 3,782 | $54K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 2,734 | 2,282 | $49K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.8% | 419 | 407 | $48K |
111 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 3,541 | $44K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.6% | 2,111 | $43K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 4,606 | $40K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 304 | $38K |
| 84484 | 1.2% | 4,100 | $32K | |
| 83880 | 1.2% | 1,483 | $32K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 739 | $30K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 2,668 | $28K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 552 | $25K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,013 | $24K |
| 87040 | <1% | 2,119 | $23K | |
| 81025 | <1% | 2,315 | $21K | |
| 82550 | <1% | 3,880 | $21K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,166 | $19K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,979 | $19K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 554 | $18K |
| 87088 | <1% | 2,101 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 912 | $17K |
| 85027 | <1% | 2,683 | $16K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,084 | $16K |
| 83605 | <1% | 1,692 | $15K | |
| 83690 | <1% | 1,963 | $15K | |
| 80305 | <1% | 1,014 | $15K | |
| 81001 | <1% | 4,742 | $14K | |
| 80061 | Lipid panel | <1% | 1,071 | $14K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,529 | $13K |
| 73560 | <1% | 494 | $12K | |
| 87631 | <1% | 135 | $12K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 60 | $11K |
| 82150 | <1% | 1,165 | $9K | |
| 82077 | <1% | 451 | $9K | |
| 87077 | <1% | 987 | $9K | |
| 80050 | General health panel | <1% | 189 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 190 | $7K |
| 81003 | <1% | 2,789 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,299 | $7K |
| 83735 | <1% | 1,227 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 848 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 392 | $6K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 114 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,580 | $5K |
| 99283 | Emergency room visit (moderate) | <1% | 861 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,460 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,822 | $5K |
| 87186 | <1% | 921 | $5K | |
| 82962 | <1% | 883 | $5K | |
| 99284 | Emergency room visit (serious) | <1% | 689 | $4K |
| 73130 | <1% | 110 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 27 | $4K |
| 73610 | <1% | 180 | $4K | |
| 73030 | <1% | 162 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 343 | $4K |
| 80076 | <1% | 254 | $3K | |
| 87807 | <1% | 274 | $3K | |
| 82803 | <1% | 142 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 203 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 437 | $2K |
| 85610 | <1% | 704 | $2K | |
| 97001 | <1% | 71 | $2K | |
| 80320 | <1% | 153 | $2K | |
| 85379 | <1% | 224 | $2K | |
| 72100 | <1% | 79 | $2K | |
| 71020 | <1% | 133 | $2K | |
| 71010 | <1% | 294 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $2K |
| 97161 | <1% | 14 | $1K | |
| 82375 | <1% | 120 | $1K | |
| 73630 | <1% | 53 | $1K | |
| 90715 | <1% | 73 | $1K | |
| 96376 | <1% | 90 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 56 | $989.82 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 36 | $896.64 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 852 | $761.84 |
| 80306 | <1% | 52 | $676.67 | |
| 74018 | <1% | 25 | $556.64 | |
| 85730 | <1% | 128 | $524.95 | |
| 87420 | <1% | 30 | $434.58 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 44 | $428.79 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 210 | $410.15 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 98 | $407.93 |
| 86901 | <1% | 13 | $350.00 | |
| 84703 | <1% | 33 | $348.82 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,584 | $333.44 |
| 80143 | <1% | 14 | $264.48 | |
| 82947 | <1% | 55 | $258.12 | |
| 36600 | <1% | 148 | $246.00 | |
| 80179 | <1% | 13 | $245.84 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 647 | $151.08 |
| 83540 | <1% | 28 | $142.29 | |
| 83550 | <1% | 28 | $142.06 | |
| 82248 | <1% | 32 | $124.76 | |
| 84436 | <1% | 15 | $121.52 | |
| 81015 | <1% | 48 | $102.33 | |
| 85007 | <1% | 46 | $93.48 | |
| 84100 | <1% | 14 | $49.29 | |
| J2704 | Injection, propofol, 10 mg | <1% | 31 | $46.64 |
| 86900 | <1% | 13 | $42.60 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 132 | $36.47 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16 | $15.90 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 320 | $3.06 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,898 | $0.19 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 101 | $0.16 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 12 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 659 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,797 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 89 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 31 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 20 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 34 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 25 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELLS, TROY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Baptist Health Regional Hospitals | Fort Smith, AR | $17.49M |
| Baptist Health | Little Rock, AR | $16.48M |
| Baptist Health | North Little Rock, AR | $14.02M |
| Baptist Health | Arkadelphia, AR | $4.82M |
| Conway Community Services | Conway, AR | $4.12M |
| Baptist Health | Heber Springs, AR | $3.69M |
| Baptist Health Hospitals | Stuttgart, AR | $2.97M |
| Baptist Health | Little Rock, AR | $2.93M |
| Baptist Health Regional Hospitals | Van Buren, AR | $2.46M |
| Baptist Health | Little Rock, AR | $1.83M |
| Baptist Health | Arkadelphia, AR | $1.51M |
| Baptist Health Hospitals | Stuttgart, AR | $901K |
| Baptist Health | Little Rock, AR | $780K |
| Baptist Health | North Little Rock, AR | $411K |
| Baptist Health | Monticello, AR | $367K |
| Baptist Health | Conway, AR | $142K |
| Baptist Health | Little Rock, AR | $88K |
| Baptist Health | Prescott, AR | $33K |
| Baptist Health | Malvern, AR | $31K |
| Baptist Health | Heber Springs, AR | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.